ArticleFrontiers in oncology2020

Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2- Breast Cancer Patient With High Tumor Mutational Burden.

Rong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.